相关实验视频

Updated: Jun 12, 2025

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

表面功能化纳米纤维:通过对葡萄糖敏感的胰岛素输送和氧化应激减轻糖尿病管理的双重作用

Bhaben Sharmah^1,2, Hiranmoy Barman^1,2, Nazim Uddin Afzal^1,2

¹Center for Infectious Diseases, CSIR-North East Institute of Science and Technology, Jorhat, Assam 785006, India.

ACS biomaterials science & engineering

|September 26, 2024

概括

这项研究介绍了一种基于纳米纤维的新型系统,用于糖尿病患者的口服胰岛素输送. 该系统有效地以对葡萄糖的反应方式输送胰岛素,降低血糖,并减少氧化应激,而无毒性.

科学领域:

生物材料科学生物材料科学
纳米技术纳米技术
药物输送系统药物输送系统

背景情况:

糖尿病 (DM) 是一个重大的健康挑战,其特点是高血糖和氧化应激增加.
目前的胰岛素疗法经常面临诸如生物可用性差,侵入性施用和低血糖风险等局限性.
纳米 (NC) 在药物输送和氧化应激调节方面表现有前途,使其适合DM管理.

研究的目的:

开发一种可响应葡萄糖的口服胰岛素输送系统,使用酸功能化纳米,加上戴克斯 (NC-PBA-INS-Dex).
评估NC-PBA-INS-Dex在糖尿病模型中调节高血糖和氧化应激的疗效.
评估新型纳米载体系统的安全性和生物可用性.

主要方法:

合成和表征NC-PBA-INS-Dex纳米颗粒具有高胰岛素负载和封装效率.
在无细胞和细胞模型 (肌肉和肺细胞) 中对对葡萄糖反应性胰岛素释放的体外评估.
在糖尿病动物模型中进行体内研究,以评估血糖控制,胰岛素生物可用性,ROS清除和肠道透性.

主要成果:

NC-PBA-INS-Dex显示了有利的胰岛素加载和封装.
在体外观察到显著的葡萄糖反应性胰岛素释放,特别是在肌肉细胞中,增强葡萄糖吸收.
在体内研究显示,单次口服剂量后12小时持续正常血糖,改善胰岛素生物可用性和有效的ROS清理.
这些纳米颗粒通过可逆地打开紧密的连接点而促进了肠道运输,而不会产生毒性.

结论:

NC-PBA-INS-Dex提供了一个有前途的非侵入性,口服输送胰岛素的策略,模仿生理分泌.
这个系统有效地管理糖尿病的高血糖和氧化应激.
开发的纳米载体系统提高了患者的服从性,并降低了与传统胰岛素治疗相关的风险.

关键词:

氧化纳米颗粒的氧化.糖尿病管理糖尿病管理清理自由基的清理方法提供胰岛素的胰岛素输送.氧化应激是一种氧化应激.

更多相关视频

Surface Engineering of Pancreatic Islets with a Heparinized StarPEG Nanocoating

Surface Engineering of Pancreatic Islets with a Heparinized StarPEG Nanocoating

Published on: June 23, 2018

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

相关概念视频

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...